


JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2019

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Half Year Ended		Previous Year Ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income						
	(a) Revenue From Operations	482.43	291.09	751.33	773.52	1,337.16	2,543.16
	(b) Other Income	28.36	25.29	51.95	53.65	75.92	93.71
	Total income	510.79	316.38	803.28	827.17	1,413.08	2,636.87
2	Expenses						
	(a) Cost of Material Consumed	38.98	37.78	42.11	76.76	79.01	164.18
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefit expense	207.77	196.64	212.30	404.41	379.32	791.61
	(e) Finance Cost	62.25	57.16	49.06	119.41	87.41	171.14
	(f) Depreciation and Amortisation expense	99.72	98.25	86.53	197.97	150.78	307.45
	(g) Other Expenses	267.09	187.52	276.73	454.61	526.78	1,040.51
	Total Expenses	675.81	577.35	666.73	1,253.16	1,223.30	2,474.89
3	Profit before exceptional items and Tax	-165.02	-260.97	136.55	-425.99	189.78	161.98
4	Add(+)/Less(-) Exceptional items	-	-	-	-	-	-
5	Profit before Tax	-165.02	-260.97	136.55	-425.99	189.78	161.98
6	Tax Expenses	34.53	57.51	-9.94	92.04	0.20	26.03
7	Profit(Loss) for the Period from Continuing Operations	-130.49	-203.46	146.49	-333.95	189.58	135.95
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-



(Handwritten signature)

Sl.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	-130.49	-203.46	146.49	-333.95	189.58	135.95
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-8.09	0.34	-0.39	-7.75	0.50	1.94
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-0.10	-	-0.10	-0.54
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	-138.58	-203.12	146.00	-341.70	189.98	137.35
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve				1405.03	1,799.37	1,746.73
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	-0.91	-1.33	0.95	-2.23	1.24	0.90
	b) Diluted (Amount in Rupees)	-0.91	-1.33	0.95	-2.23	1.38	0.94
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)	-	-	-	-	-	-
	b) Diluted (Amount in Rupees)	-	-	-	-	-	-
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	-0.91	-1.33	0.95	-2.23	1.24	0.90
	b) Diluted (Amount in Rupees)	-0.91	-1.33	0.95	-2.23	1.38	0.94

Notes to the Standalone Un Audited Financial Results


- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 13.11.2019 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- The Figures for the Quarter Ended 30-09-2019 are the balancing figures between the unaudited figures for the Half year and the published year to date figures for the period 30th June, 2019.
- During the year Company is operating in only one segment i.e., Clinical Research Services
- The Company has adopted Ind As-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the company.
- Figures for the previous periods have been rearranged wherever necessary.

Place:Hyderabad
Date:13.11.2019




SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Stand Alone Unaudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2019

Particulars	Quarter Ended			Half Year Ended		Rupees in Lakhs
	30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	Previous Year Ended
	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	31-03-2019 Audited
SEGMENT REVENUE: (Net Sales / Income from Operations)						
a) Clinical Research Services	510.79	316.38	751.33	827.17	1,337.16	2,636.87
b) Information Technology Services	-	-	-	-	-	-
c) Data Management Services	-	-	-	-	-	-
d) Unallocable income	-	-	51.95	-	75.92	-
Total:	510.79	316.38	803.28	827.17	1,413.08	2,636.87
LESS: Inter Segment revenue	-	-	-	-	-	-
Net Sales/ income from Operations.	510.79	316.38	803.28	827.17	1,413.08	2,636.87
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST						
a) Clinical Research Services	-102.77	-203.81	133.66	-306.58	201.27	333.12
b) Information Technology Services	-	-	-	-	-	-
c) Data Management Services	-	-	-	-	-	-
Total:	-102.77	-203.81	133.66	-306.58	201.27	333.12
LESS:						
i) Interest	62.25	57.16	49.06	119.41	87.41	171.14
ii) Other Un-Allocable Expenditure	-	-	-	-	-	-
iii) Un-Allocable Income	-	-	-51.95	-	-75.92	-
TOTAL PROFIT /(-LOSS) BEFORE TAX	-165.02	-260.97	136.55	-425.99	189.78	161.98



Jeevan Scientific Technology Limited		
Stand Alone Balance Sheet as at 30th Sep, 2019		
(Rupees in Lakhs)		
Particulars	As at 30.09.2019	As at 31.03.2019
Assets		
(1) Non-current Assets		
a) Property, Plant and Equipment	1,839.88	1,956.77
b) Other Intangible Assets	73.47	73.19
c) Intangible Assets Process Knowhow	577.21	630.80
d) Financial Assets		
i) Investments	102.69	102.69
ii) Loans	556.28	476.27
iii) Advances	369.55	382.74
c) Deferred tax asset (net)	53.88	-
(2) Current Assets		
a) Inventories	22.13	23.04
b) Financial Assets		
i) Trade receivables	1,252.19	1,450.62
ii) Cash and cash equivalents	413.42	359.95
iii) Bank balances other than (ii) above	5.63	5.63
iv) Loans & Advances (current)	48.22	41.18
v) Other Financial Assets	144.66	110.03
c) Current Tax Assets (Net)	465.19	439.06
d) Other Current Assets	17.12	29.70
Total	5,941.50	6,081.70
Equity and Liabilities		
Equity		
a) Equity Share Capital	1,530.15	1,530.15
b) Other Equity	1,405.03	1,746.73
Liabilities		
(1) Non-current Liabilities		
a) Financial liabilities		
Borrowings	1,031.93	746.55
b) Provisions	23.44	18.10
c) Deferred tax Liability (net)	-	38.16
(2) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	753.90	725.76
ii) Trade Payables	308.17	243.66
iii) Other Financial liabilities	370.02	398.29
iv) Other Financial Creditors	206.30	193.94
b) Other current liabilities	287.80	391.07
c) Provisions	24.77	49.30
Total	5,941.50	6,081.70



[Handwritten signature]

Jeevan Scientific Technology Limited			
Stand Alone Cash flow statement for the year ended 30th September, 2019			
		(Rupees in Lakhs)	
S.No	Particulars	As at 30.09.2019	As at 30.09.2018
A.	Cash flow from operating activities		
	Net Profit before tax and extraordinary items	-341.70	189.78
	Adjustments for:		
	Depreciation	197.97	162.60
	Loss on Sale of Assets	-	-
	Interest	117.05	87.73
	Operating profit before working capital changes	-26.68	440.12
	Adjustments for:		
	Inventories	0.91	-7.86
	Trade and other receivables	76.42	-670.40
	Trade and other Paybles	137.76	-183.73
	Cash generated from operations	-87.10	-54.40
	Taxes Provision		
	Interest paid	117.05	87.73
	Net cash from operating activity	-204.15	-142.14
B.	Cash flow from investing activities		
	Purchase of fixed assets	27.76	395.89
	Investments	-	-
	Sale/ Transfer of fixed assets	-	-
	Net cash used in investing activity	-27.76	-395.89
C.	Cash flow from financing activity		
	Proceeds from loans	285.38	-158.16
	Increase in Capital	-	384.20
	Increase in Other Equity	-	485.12
	Net cash generated in financing activity	285.38	711.16
	Net increase in cash and cash equivalents (A+B+C)	53.46	173.13
	Cash and cash equivalents as at the beginning of the period	365.59	137.29
	Cash and cash equivalents as at the end of the period	419.05	310.42

Place:Hyderabad
Date: 13.11.2019

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

K. Krishna Kishore
K. Krishna Kishore
Vice Chairman & Managing Director

